Return to homepagePandemic Pact

COVID-19 Therapeutic Accelerator - Support to Phase III Development and Registration of the Anti-Malaria Drug Pyramax for the Treatment of COVID-19.

  • Funded by Foreign, Commonwealth & Development Office (FCDO)
  • Total publications:0 publications

Grant number: GB-1-204765-115

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2022

  • Known Financial Commitments (USD)

    $12,794,904.85

  • Funder

    Foreign, Commonwealth & Development Office (FCDO)

  • Principal Investigator

    N/A

  • Research Location

    Switzerland

  • Lead Research Institution

    Medicines for Malaria Venture (MMV)

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

General: This activity COVID-19 Therapeutic Accelerator - Support to Phase III Development and Registration of the Anti-Malaria Drug Pyramax for the Treatment of COVID-19. is a component of Epidemics and Global Health Security Research Programme (Epidemics and GHS) reported by FCDO with a funding type of 111 - Not for profit organisation and a budget of £9,469,157. This project benefits Developing countries, unspecified. It works in the following sector(s): Medical research.; General: This activity COVID-19 Therapeutic Accelerator - Support to Phase III Development and Registration of the Anti-Malaria Drug Pyramax for the Treatment of COVID-19. is a component of Epidemics and Global Health Security Research Programme (Epidemics and GHS) reported by FCDO with a funding type of 111 - Not for profit organisation and a budget of £9,469,157. This project benefits Developing countries, unspecified. It works in the following sector(s): Medical research.